Most guides to hair loss medication read like product pages. This one includes the parts that regulators have been strengthening warnings about, because you can't weigh a treatment properly if you only see one side of it.

Start here: these are prescription decisions

Everything below is prescription medication, some of it prescribed off-label for hair loss. None of it should be started, stopped or dosed on the basis of a website — including this one. What an article can do is tell you what exists, what the evidence says, and what to raise with a doctor.

Finasteride

What it does. Finasteride blocks 5-alpha reductase, the enzyme converting testosterone to DHT — the hormone driving follicle miniaturisation in male pattern hair loss. It's the most studied oral treatment for the condition, and the manufacturer's original trials reported that a large majority of men stopped losing hair and a substantial proportion saw some regrowth over two years. Effects take 6–12 months to judge, and stop when the drug stops.

What the safety warnings say. This is where most guides go quiet, so here it is directly.

In June 2025, following an EU-wide review, the European Medicines Agency's safety committee confirmed suicidal ideation as a side effect of finasteride tablets. The frequency is listed as unknown — the data doesn't allow an estimate. Most reported cases were in people taking the 1 mg dose, which is the dose used for hair loss. EU product information now advises patients experiencing mood changes to seek medical advice and, on the 1 mg dose, to stop treatment.

The UK's MHRA has similarly strengthened its warnings, stating that finasteride is associated with depression, suicidal ideation and sexual dysfunction which may persist after treatment is stopped. It advises prescribers to ask about any history of depression or suicidal ideation before prescribing, and UK packs have carried patient alert cards since 2024. UK adverse-event data recorded to May 2025 includes 170 reports of suicidal ideation for finasteride and 19 fatal reports of suicide.

Adverse-event reports don't prove the drug caused each case, and millions of men take finasteride without difficulty. But "a minority experience side effects that resolve on stopping" — the reassurance repeated across most hair-loss content — is not what the regulators currently say.

Two things often left out. Finasteride is contraindicated in women who are or may become pregnant, because it can cause abnormalities in a male fetus; women of childbearing potential shouldn't handle crushed or broken tablets. And finasteride roughly halves PSA levels, so anyone having prostate screening needs to tell the doctor ordering the test.

What to do with this. Not necessarily to avoid finasteride — many men take it with good results and no problems. But to go in informed: mention any history of depression or anxiety to your prescriber, know that mood change is a reason to seek advice rather than push through, and make the decision with a doctor who discusses this openly.

Minoxidil

Minoxidil works on a different mechanism — it doesn't touch DHT. Topical minoxidil is available over the counter and is the most widely used treatment for pattern hair loss. Low-dose oral minoxidil, originally a blood-pressure medication, is increasingly prescribed off-label by dermatologists and can be more convenient than topical application, but because of its cardiovascular origins it needs prescribing and monitoring by a doctor who knows your history.

The most commonly reported side effect at low doses is increased fine body hair. Minoxidil carries no regulatory warning comparable to finasteride's — which is worth knowing if the psychiatric risk profile of 5-alpha reductase inhibitors concerns you.

Topical finasteride

Often presented as the safer route — scalp-level DHT suppression with less systemic absorption. Absorption is lower, but it isn't zero, and the safety picture is less settled than the marketing suggests: the FDA has issued a safety alert about compounded topical finasteride products, based on adverse-event reports in which most effects continued after the product was stopped. Treat it as a discussion to have with a dermatologist, not as a risk-free version.

Dutasteride

Dutasteride inhibits both types of 5-alpha reductase rather than one, producing greater DHT suppression, and studies show stronger regrowth than finasteride in some patients. It's approved for enlarged prostate and used off-label for hair loss.

Two things to weigh: side effects are broadly similar to finasteride's and potentially more pronounced given the greater suppression; and dutasteride stays in the body far longer — weeks rather than hours — so if problems arise, they take much longer to clear. The MHRA's 2025 review included dutasteride and issued precautionary advice, though it did not find the same direct link to suicidal ideation that it confirmed for finasteride.

Medication alongside a hair transplant

This is where medication becomes relevant to surgery. A transplant doesn't stop native hair loss — so without maintenance, transplanted hair can end up as an island in front of continuing recession, which is why most surgeons discuss medical therapy alongside surgery.

That's a genuine clinical consideration, and also a genuine decision: it means committing to a long-term medication with the risk profile described above. Some men accept that trade-off; others plan a conservative, future-proofed design instead and skip the drug. Both are legitimate, and a good surgeon will discuss the second option rather than treating medication as automatic.

The honest summary

Finasteride is effective and, for many men, uneventful. It also has a safety profile that regulators strengthened warnings about in 2025, including effects that may not resolve on stopping. Minoxidil is a different mechanism with a different, milder risk picture. Anyone telling you these are simple choices is selling something.

Take the question to a doctor who will discuss both sides — and if any medication affects your mood, that's a reason to seek advice promptly, not to wait it out.

This is general information, not medical advice, and is not a substitute for a prescribing clinician. If you experience mood changes, depression or thoughts of self-harm while taking any medication, seek medical advice promptly. In the US, the 988 Suicide & Crisis Lifeline is available by call or text; in the UK and Ireland, Samaritans on 116 123. Foxpare is an information and matching service, not a medical provider.

Sources

  • European Medicines Agency. Measures to minimise risk of suicidal thoughts with finasteride and dutasteride medicines. EMA/202053/2025, August 2025 (PRAC recommendation endorsed by CMDh, June 2025).
  • MHRA. Finasteride and dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction. Drug Safety Update, 2025.
  • MHRA Yellow Card data, 1994 – 31 May 2025.
  • US FDA safety communication on compounded topical finasteride products.